Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Sheba Joins Peter Mac for a New Prostate Cancer Treatment Trial

Sheba and Peter Mac
The two medical centers will collaborate on a new trial designed to evaluate innovative treatments for men suffering from advanced prostate cancer.

The POPSTAR II clinical trial, due to begin in early 2023 at multiple sites, will compare two cutting-edge treatments for men with advanced prostate cancer – lutetium PSMA (LuPSMA) therapy and stereotactic ablative radiotherapy (SABR). During a recent visit to Australia, Sheba’s Director General, Prof. Yitshak Kreiss, signed a letter of intent making Sheba an international partner for the new trial.

After visiting Israel, Peter Mac Chief Executive. Prof. Shelley Dolan, described this latest agreement as another example of the growing international relationship between two leading institutions.

“The international expansion of this clinical trial will boost access for men to innovative prostate cancer treatments,” Prof. Dolan explained. “Following the signing of an MOU between Peter Mac and Sheba Medical Center, it is fantastic to see that it is being implemented for the benefit of people with cancer internationally.”

The aforementioned MOU was signed in May when both organizations agreed to collaborate on innovation and commercialization opportunities, research and scientific collaborations, educational and training opportunities, fellowship programs, staff exchanges, and more.

Commenting on the new agreement, Professor Kreiss stressed: “We see our collaboration with Peter Mac as an important step toward strengthening our relationship with the Victorian Government in relation to innovation and clinical research. Peter Mac is an elite institution that is a leader in research and the development of novel treatments. It endeavors to change the future of medicine, mirroring Sheba’s vision via our ARC innovation center.”

Home to some of the world’s top experts in cancer research, and prostate cancer in particular, Sheba is proud to play a leading role in the development of advanced therapies for the benefit of patients worldwide.

News Mar 26.
West Bank and Gaza Medical Professionals Attend a Milestone Sheba Oncology Conference
Highlighting the latest in cancer care, with a particular focus on pediatrics, the Recent Advances in Cancer Care (REACT) 2023 event was attended by over…
Read More
Isenia’s Battle
Isenia’s Battle with Alveolar Sarcoma
At 17, Isenia, a native of Semey, Kazakhstan, noticed a lump on her leg the size of a small apple. Initially, Isenia and her family…
Read More
Colon and Rectal Cancer
News Mar 14.
Sheba Study Indicates Readily-Available Drugs May Prevent Metastasis in Colon and Rectal Cancer Patients
Favorable responses to the treatment were noted by Prof. Shamgar Ben-Eliyahu, a neuroscientist specializing in psychoneuroimmunology (PNI) at TAU’s Sagol School of Neuroscience and School…
Read More